Powerful cocktail shows promise against bone marrow cancer

NCT ID NCT02969837

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of four drugs—elotuzumab, carfilzomib, lenalidomide, and dexamethasone—in 46 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep response (stringent complete response or minimal residual disease negativity). The study found that the combination led to high response rates, suggesting it could be a strong initial treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elotuzumab, carfilzomib, lenalidomide, dexamethasone
What this could lead to: If successful, this combination could become a powerful first-line treatment for multiple myeloma, potentially leading to deeper remissions and longer survival.
What could go wrong: This is a small, single-arm phase 2 study with no comparison group, so results may not hold up in larger trials. Side effects from the drug combination can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

NorthShore University Health System

Evanston, Illinois, 60201, United States
University of Chicago

Chicago, Illinois, 60637, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.